fundsforNGOs
Grants and Resources for Sustainability
Deadline: 07-Jul-2026
Pfizer has launched a competitive research grant program to support projects that use artificial intelligence (AI) and advanced clinical decision support (CDS) systems to improve timely and safe access to nirmatrelvir/ritonavir treatment for eligible COVID-19 patients. Individual research projects can receive up to USD 500,000 for a maximum duration of two years, with funding available to eligible organizations in selected countries.
Pfizer is inviting research proposals that leverage artificial intelligence (AI) and advanced clinical decision support technologies to improve the delivery of outpatient COVID-19 antiviral treatment.
The program aims to address barriers that prevent eligible patients from receiving nirmatrelvir/ritonavir within the recommended treatment window. Successful projects should develop innovative solutions that help healthcare providers identify eligible patients quickly, manage potential drug–drug interactions (DDIs), and improve treatment outcomes.
The initiative supports evidence-based research that combines healthcare innovation, digital health technologies, and clinical decision-making to improve patient care.
The Pfizer AI Research Grant provides financial support for eligible research projects.
Funding Details
The grant program aims to:
Projects should address one or more of the following priorities:
Research may include:
Projects may develop:
Research should improve:
Projects are encouraged to develop solutions that:
Early treatment plays a critical role in reducing severe outcomes among high-risk COVID-19 patients.
Starting nirmatrelvir/ritonavir within five days of symptom onset can help:
AI-enabled clinical tools can help ensure eligible patients receive treatment within this important therapeutic window.
Eligible research projects may include:
Projects should address barriers to delivering timely outpatient antiviral therapy.
Only organizations may apply for funding.
Eligible organizations must be based in one of the following countries:
Both the organization and the proposed Principal Investigator (PI) must satisfy Pfizer’s eligibility requirements.
The Principal Investigator must hold one of the following qualifications:
The PI must also:
The applicant organization must:
Only organizations—not individuals—are eligible to receive grant funding.
Successful projects should demonstrate:
Projects should produce practical solutions that can improve outpatient COVID-19 care.
Artificial intelligence has the potential to transform healthcare by improving clinical decision-making and reducing treatment delays.
This Pfizer funding opportunity supports innovations that can:
Applicants should follow these general steps:
To improve your chances of success:
Avoid these common application errors:
It is a competitive funding opportunity supporting research projects that use artificial intelligence and advanced clinical decision support solutions to improve access to nirmatrelvir/ritonavir treatment for eligible COVID-19 patients.
Individual projects may request up to USD 500,000 for a maximum project duration of two years.
Only eligible organizations located in Australia, Canada, Germany, Greece, Japan, Korea, or Taiwan may apply. Individuals cannot receive funding directly.
Eligible projects include AI-enabled eligibility assessment, clinical decision support systems, drug–drug interaction management tools, digital health innovations, and outpatient COVID-19 treatment improvement initiatives.
The PI must hold a medical, postdoctoral, advanced nursing, pharmacy, physiotherapy, or social work degree and be employed by or contracted to the applicant organization.
Initiating nirmatrelvir/ritonavir within five days of symptom onset can significantly reduce the risk of severe illness, hospitalization, and death among high-risk COVID-19 patients.
Strong proposals demonstrate innovative AI applications, robust clinical relevance, effective drug–drug interaction management, measurable patient outcomes, realistic implementation plans, and clear alignment with the program’s objectives.
The Pfizer AI Research Grant Program offers up to USD 500,000 to support innovative research that improves timely and safe access to COVID-19 antiviral treatment through artificial intelligence and advanced clinical decision support. By funding projects that enhance patient eligibility assessment, optimize drug–drug interaction management, and strengthen outpatient care, the program seeks to advance digital health innovation and improve clinical outcomes for high-risk COVID-19 patients worldwide.
For more information, visit Pfizer.
Funds for NGOs
Funds for Companies
Funds for Media
Funds for Individuals
Sample Proposals
Contact us
Submit a Grant
Advertise, Guest Posting & Backlinks
Fight Fraud against NGOs
About us
Terms of Use
Third-Party Links & Ads
Disclaimers
Copyright Policy
General
Privacy Policy
Premium Sign in
Premium Sign up
Premium Customer Support
Premium Terms of Service
©FUNDSFORNGOS LLC. fundsforngos.org, fundsforngos.ai, and fundsforngospremium.com domains and their subdomains are the property of FUNDSFORNGOS, LLC 1018, 1060 Broadway, Albany, New York, NY 12204, United States. Unless otherwise specified, this website is not affiliated with the abovementioned organizations. The material provided here is solely for informational purposes and without any warranty. Visitors are advised to use it at their discretion. Read the full disclaimer here. Privacy Policy. Cookie Policy.
Leave a Reply